Anavex Life Sciences Announces FDA Approval of IND for Phase 2 Trial of ANAVEX®2-73 in Patients with Rett Syndrome

Anavex Life Sciences Announces FDA Approval of IND for Phase 2 Trial of ANAVEX®2-73 in Patients with Rett Syndrome Study will incorporate genomic precision medicine ANAVEX®2-73-specific biomarkers NEW YORK – October 19, 2018 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of…